Skip to main content
GutCited

Lactobacillus gasseri per Helicobacter pylori Infection

B

Three RCTs show L. gasseri LG21 suppresses H. pylori load and improves eradication rates when combined with standard triple therapy. Also improves GERD symptoms.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Dgasseri\u0026condition\u003Dh\u002Dpylori'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

In sintesi

Three RCTs show L. gasseri LG21 suppresses H. pylori load and improves eradication rates when combined with standard triple therapy. Also improves GERD symptoms.

Key Study Findings

In Vitro
Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in …
Dose: None vs: H. pylori infection without lactobacilli Outcome: ADAM17, HBEGF, TGF-alpha expression Effetto: None None

Popolazione: AGS gastric epithelial cells and mouse model

In Vitro
Lactobacillus gasseri Suppresses the Helicobacter pylori-Induced Hummingbird Phenotype by Inhibiting CagA Phosphorylation and SHP-2 Interaction.
Dose: None vs: CagA-expressing AGS cells without L. gasseri Outcome: Suppression of CagA phosphorylation (hummingbird) Effetto: None None

Popolazione: Human gastric AGS cell line with H. pylori CagA

In Vitro
The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of …
Dose: 50 μg/ml vs: None Outcome: Inflammatory markers Effetto: None None

Popolazione: None

Other
Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter …
Dose: None vs: None Outcome: Inflammatory markers Effetto: None None

Popolazione: Cancer patients

Other
Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori …
Dose: None vs: None Outcome: H. pylori abundance reduction Effetto: None None

Popolazione: H. pylori-infected C57BL/6 mice

Case-Control n=178
Oral and gastric microbiome in relation to gastric intestinal metaplasia.
Dose: None vs: None Outcome: Oral/gastric microbiome associations with IM Effetto: None None

Popolazione: Gastric intestinal metaplasia cases and matched controls

Key Statistics

3

Studi

350

Partecipanti

Positive

B

Grado

Referenced Papers

International journal of … 2022 59 citazioni
Comparative immunology, microbiology … 2019 72 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
1-10 billion CFU/day
gerdsupport:
1-5 billion CFU/day
hpylorisupport:
100 million CFU/day (LG21 strain, yogurt form) for 8-12 weeks

Limite massimo: Well-tolerated up to 10 billion CFU/day in clinical trials

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Positive --
None -- Positive --
50 μg/ml -- Mixed --
None -- Positive --
None -- Positive --
None -- Neutral 178
None -- Positive --
1 g -- Positive --

Momento migliore per l'assunzione: Before meals or with meals; yogurt form taken with food

Safety & Side Effects

Effetti collaterali segnalati

  • Mild gas during initial use
  • Occasional loose stools
  • Rare abdominal discomfort
  • Very rare: bacteremia in immunocompromised individuals

Interazioni note

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Proton pump inhibitors (altered gastric pH may affect colonization)
  • Immunosuppressants (theoretical risk in immunocompromised patients)

Livello di assunzione massimo tollerabile: Well-tolerated up to 10 billion CFU/day in clinical trials

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Lactobacillus gasseri help with Helicobacter pylori Infection?
Based on 3 studies with 350 participants, there is moderate evidence from clinical studies that Lactobacillus gasseri may support Helicobacter pylori Infection management. Our evidence grade is B (Good Evidence).
How much Lactobacillus gasseri should I take for Helicobacter pylori Infection?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus gasseri?
Reported side effects may include Mild gas during initial use, Occasional loose stools, Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus gasseri and Helicobacter pylori Infection?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.

Related Evidence

Altri ingredienti per Helicobacter pylori Infection

Lactobacillus gasseri per altre condizioni

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.